Our innovative processes include protocol design, site training, and real time data quality analysis
Clinical understanding of neurobiology is incomplete, contributing to clinical development programs in Central Nervous System (CNS) having the highest failure rates across all therapeutic areas. CNS clinical trials bring specific challenges including managing placebo response, incorporating soft endpoints, and a particular focus on reducing patient burden.
Unsurprisingly this had led to a challenging of accepted and established norms by CNS drug developers.
We support sponsors in minimising development risk and maximising probability of success through:
- Access to the latest, applied technology innovation and processes
- Working with our highly qualified and therapeutically trained staff
- Real time data quality monitoring and analysis
ICON's experienced neuroscience and drug development teams work across all areas of CNS research including:
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Diabetic Peripheral Neuropathy
- Multiple Sclerosis
- Parkinson’s Disease
Acute and Chronic Pain
- Inflammatory / soft tissue injuries
- Low back pain
- Migraine pain
- Neuropathic pain
- Rheumatoid and osteoarthritis pain
- Depressive disorders
- Biopolar disorder
ICON CNS experience in last five years
Services for CNS, Pain and Ageing Diseases
Our Protocol Optimisation and Clinical Development Plans service is complemented with Adaptive Design competency and regulatory approved software. Our full service study/program implementation and execution includes:
Dedicated specialist teams
All staff assigned to projects including; Project Management, Drug Development, Site Identification and Feasibility, and Medical oversight attend customised training programs. Over the past 5 years ICON have conducted phase II & III studies in a range of CNS indications. We also offer dedicated teams for rare and paediatric CNS programs.
Whitepaper: Key considerations for trials in chronic pain
The opioid crisis has created an urgent need for innovative pain medications without the use of opioids. Unfortunately, clinical development of non-opioid pain medications, such as non-steroidal anti-inflammatory drugs (NSAIDS), has been hindered by a massive placebo-response. In this whitepaper, we discuss the aspects of pain studies that sponsors will need to consider to ensure success of their chronic pain trial model.